Formycon AG logo — The Biosimilar Experts

Formycon AG

The Biosimilar Experts

Founded 2012 Germany Planegg, Germany 171 employees Post Ipo Equity Total: $83.13M Biopharma

General Information

Company Name Formycon AG
Founded Year 2012
Location Germany Planegg, Germany +1
Employees 171
Industries Biopharma
Funding Stage Post Ipo Equity
Social

Get notified when Formycon AG moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Formycon AG

Formycon AG is a biopharmaceutical company based in Germany and was founded in 1999. The company's mission, coined as The Biosimilar Experts, is to develop high-quality biopharmaceutical medicines, especially biosimilars, with a focus on treatments in ophthalmology, immunology, and other key chronic diseases. Formycon covers the entire value chain from technical development to clinical phase III and the preparation of dossiers for marketing approval. Currently, the company has four biosimilars in development, and it is also working on a COVID-19 drug FYB207. Biosimilars have promising growth prospects, as many biotech drugs are expected to lose their patent protection in the next decade. Analysts estimate that the global sales of biosimilars could exceed $15 billion by 2020 and rise to over $60 billion by 2030. The company's last investment was a €82.84M Post-IPO Equity investment on 29 January 2024, with the investment coming from the Richter Group. Formycon's expertise and dedication to providing affordable medicines to patients indicate potential success in the rapidly growing biosimilars market. With its innovative approach to biopharmaceutical development and a strong investor backing, Formycon AG seems well-positioned to capitalize on the expanding opportunities in the biopharmaceutical industry.

For more information, visit Formycon AG at Fraunhoferstr. 15, 82152 Martinsried/Planegg, Germany. Contact them via phone at +49 (0) 89 - 86 46 67 100 or email at [email protected].

Taxonomy: Biosimilars, Biopharmaceuticals, Ophthalmology, Immunology, Chronic Diseases, Drug Development, Clinical Trials, Regulatory Approval, Biotech Drugs, COVID-19 Drug, GMP Quality Control, Formulation Development, Analytical Services, CMC Regulatory Affairs, Project Management

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 1 •••• •••• 29 Jan 2024
Grant •••••• 1 •••• •••• 13 Oct 2020

Formycon AG Alternatives & Competitors

Formycon AG vs

SK Biopharmaceuticals is a global pioneer in the development of new drugs

Grant
233 employees
Biotechnology, Health and Wellness
Formycon AG vs

Biopharmaceutical company performing discovery, rational design and initial clinical development of...

Unknown
39 employees
Biotechnology, Life Sciences
Formycon AG vs

From lab to life

993 employees
Biopharma, Biotechnology

FAQ About Formycon AG

The Biosimilar Experts
Formycon AG was founded in 2012.
Formycon AG is headquartered in Planegg, Germany.
Formycon AG operates in the following industries: Biopharma.
Formycon AG has approximately 171 employees.
Formycon AG has completed 2 funding rounds, raising a total of $83.13M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Formycon AG include SK Biopharmaceuticals, Laminar Pharma, mAbxience, ASPHALION, AN2 Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Formycon AG and SK Biopharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Formycon AG and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy